SCHEMBL17154133

SCHEMBL17154133

Cc1ccc(S[C@H]2OC(CO)[C@@H](O)C(C)[C@@H]2OC(=O)c2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 11/20 0.60
LGALS9 O00182 6/20 0.60
LGALS1 P09382 6/20 0.60
LGALS7; LGALS7B P47929 5/20 0.59
LGALS8 O00214 3/20 0.47
LGALS4 P56470 1/20 0.45
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
SSTR4 P31391 1/20 0.41
SSTR5 P35346 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17154143 1.00 LGALS3 (0.60) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL12136352 0.94 LGALS3 (0.64) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL3817822 0.92 LGALS3 (0.65) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL5899337 0.87 LGALS3 (0.56) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL19674440 0.85 LGALS3 (0.58) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL19674473 0.85 LGALS3 (0.58) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL12585271 0.85 LGALS9 (0.57) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL16623018 0.84 LGALS3 (0.57) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL18067750 0.83 LGALS9 (0.44) LGALS3LGALS9LGALS1LGALS7; LGALS7BCA12
SCHEMBL18925426 0.83 LGALS3 (0.52) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284419-A1 METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2015-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284419-A1 METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF HABP2, HPSE, PLG LGALS3 2783/4885LGALS9 2377/4885LGALS1 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.